Trials / Completed
CompletedNCT04569435
Study of ANX005 in Adults With Amyotrophic Lateral Sclerosis (ALS)
Phase 2a Safety, Tolerability, Pharmacokinetic (PK), and Pharmacodynamic (PD) Study of Intravenous ANX005 in Subjects With Amyotrophic Lateral Sclerosis (ALS)
- Status
- Completed
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 17 (actual)
- Sponsor
- Annexon, Inc. · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
This study is a multi-center, open-label study of intravenous (IV) ANX005 in participants with ALS.
Detailed description
In this Phase 2a, multi-center, open label, proof-of-biology study, ANX005 will be administered to participants with ALS. The study consists of approximately 22 weeks of treatment and approximately 14 weeks of follow-up. All participants will be contacted by phone 6 months after study completion.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | ANX005 | IV Infusion |
Timeline
- Start date
- 2021-01-15
- Primary completion
- 2024-01-10
- Completion
- 2024-04-23
- First posted
- 2020-09-29
- Last updated
- 2025-01-06
Locations
8 sites across 2 countries: United States, Canada
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT04569435. Inclusion in this directory is not an endorsement.